Phase 2 Trial Shows Benefit From Investigational Pentavalent Vaccine For Neisseria Meningitidis

Healio (6/7, Downey) reports on a phase 2 trial in Mali that “showed promise” for “an investigational pentavalent vaccine for Neisseria meningitidis.” Specifically, the trail showed “that a single dose of the vaccine, NmCV-5, ‘elicited immune responses th...